Back to news overview

VUB spin-off Ablynx: nanobodies might save your life

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP (thrombotic thrombocytopenic purpura), a rare but lethal disease.

Check articles in De Tijd, De Standaard and by Flanders Bio.